Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943446 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery
A Phase 2 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03943446 is a Phase 2 study that was terminated before completion, run by Takeda. The registered enrollment target is 34 participants.
The verdict
NCT03943446, a Phase 2 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The main aim is to see if TAK-018 reduces the recurrence of intestinal inflammation after abdominal resection surgery in adults with Crohn's disease. Participants will take either TAK-018 or placebo tablets by mouth, 2 times each day for up to 26 weeks after surgery. The placebo looks like TAK-018 but will not have any medicine in it. Participants will have 6 study visits while receiving treatment. Visits 1 and 6 will be conducted at the study clinic. The others can be in the clinic or at the participant's home. Follow-up will occur 4 weeks after final treatment.
Interventions
- DRUG TAK-018
- DRUG TAK-018 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2022-08-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03943446
The ClinicalTrials.gov registry entry for NCT03943446 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-018 is the first listed.
NCT03943446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03943446 about?
NCT03943446 is a clinical study titled "A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery". The main aim is to see if TAK-018 reduces the recurrence of intestinal inflammation after abdominal resection surgery in adults with Crohn's disease. Participants will take either TAK-018 or placebo tablets by mouth, 2 times each day for up to 26 weeks after surgery. The placebo looks like TAK-018 ...
What is the current status of trial NCT03943446?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2020-08-04. Estimated completion is 2022-08-25.
What interventions are being tested in trial NCT03943446?
The interventions under investigation include: TAK-018 (DRUG), TAK-018 Placebo (DRUG).
Who is sponsoring clinical trial NCT03943446?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.